Trade Mark Journal No.2026/017 24 April 2026
WO0000001911695 (5,42)
Office of origin: United States of America
Date of International Registration:6 March 2026
Date of designation in the UK:
6 March 2026

International priority date claimed: 13 February 2026
(United States of America)
(99652396)
International priority date claimed: 13 February 2026
(United States of America)
(99652403)
- Class 5
- Pharmaceutical and biopharmaceutical drugs and medicines for treatment of degenerative retinal diseases.
- Class 42
- Research and development of pharmaceutical and biopharmaceutical drugs and medicines for the treatment of degenerative retinal diseases; research and development in the pharmaceutical, life sciences and biotechnology fields.
Belite Bio, Inc.
Representative: Scott W. Pink O'Melveny & Myers, LLP, 2765 Sand Hill Rd, Menlo Park CA 94025-7019, UNITED STATES OF AMERICA